Die Bedeutung von Zytokinen und Wachstumsfaktoren bei fibrosierenden Lungenerkrankungen

Zusammenfassung

Ein neues pathogenetisches Konzept zur Fibrogenese hat die Hypothese aufgestellt, dass es sich bei der Fibrose um „pathologische Wundheilung” oder gestörtes „Remodeling” handelt und Entzündungsvorgänge sekundär sind. Zytokine sind bei diesem Prozess maßgeblich involviert und ein attraktives Ziel für pharmakologische Interventionen. TGFβ hat als profibrotischer Wachstumsfaktor eine Schlüsselstellung und kann auf verschiedenen Wegen inaktiviert oder in seiner Wirkung abgeschwächt werden. Diese Übersichtsarbeit erläutert die Grundlagen der pathobiologischen Abläufe und stellt ihre potenzielle klinische Bedeutung dar.

Abstract

A new hypothesis of the pathogenesis of fibroproliferative lung disease suggests that fibrosis is caused by abnormal and excessive wound healing and pathologic tissue remodelling. Inflammation is possibly an epiphenomenon. Cytokines are critical players in the pathologic process and attractive targets for pharmacological intervention. TGFβ is a key profibrotic growth factor, a variety of approaches are known to modify and inhibit its activity. This article reviews the basic pathological concepts of pulmonary fibrogenesis and outlines its potential clinical benefit.

Literatur

• 1 Lympany P A, du Bois R M. Diffuse lung disease: product of genetic susceptibility and environmental encounters.  Thorax. 1997;  52 92-94
• 2 Gross T J, Hunninghake G W. Idiopathic pulmonary fibrosis.  N Engl J Med. 2001;  345 517-525
• 3 Ryu J H, Colby T V, Hartman T E. Idiopathic pulmonary fibrosis: current concepts.  Mayo Clin Proc. 1998;  73 1085-1101
• 4 American Thoracic Society . Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS).  Am J Respir Crit Care Med. 2000;  161 646-664
• 5 Selman M, King T E, Pardo A. Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for Therapy.  Ann Intern Med. 2001;  134 136-151
• 6 Sime P J, Gauldie J. Mechanisms of scarring. In: Evans TWHC (editor). ARDS in adults. London: Chapman & Hall Medical 1996: 215-231
• 7 Sheppard D. Pulmonary fibrosis: a cellular overreaction or a failure of communication?.  J Clin Invest. 2001;  107 1501-1502
• 8 Gauldie J, Kolb M, Sime P J. A new direction in the pathogenesis of idiopathic pulmonary fibrosis?.  Respir Res. 2002;  3 1
• 9 Lasky J A, Brody A R. Interstitial fibrosis and growth factors.  Environ Health Perspect. 2000;  108 Suppl 4 751-762
• 10 Allen J T, Spiteri M A. Growth factors in idiopathic pulmonary fibrosis: relative roles.  Respir Res. 2002;  3 13
• 11 Kunkel S L. Chemotactic cytokines: the chemokine family. In: Phan S (editor). Pulmonary fibrosis. New York: Marcel Dekker 1995: 579-597
• 12 Gauldie J, Sime P J, Xing Z. et al . Transforming growth factor-beta gene transfer to the lung induces myofibroblast presence and pulmonary fibrosis.  Curr Top Pathol. 1999;  93 35-45
• 13 Remick D. Cytokines and pulmonary fibrosis. In: Pulmonary fibrosis. New York: Marcel Dekker 1995: 599-626
• 14 Khalil N, O'Connor R N. Cytokine regulation of pulmonary fibrosis: TGFbeta. In: Pulmonary fibrosis. New York: Marcel Dekker 1995: 627-645
• 15 Keane M P, Strieter R M. The importance of balanced pro-inflammatory and anti-inflammatory mechanisms in diffuse lung disease.  Respir Res. 2002;  3 5
• 16 Ward P A, Hunninghake G W. Lung inflammation and fibrosis.  Am J Respir Crit Care Med. 1998;  157 S123-S129
• 17 Dinarello C A. Interleukin-1.  Cytokine Growth Factor Rev. 1997;  8 253-265
• 18 Rochester C L, Elias J A. Cytokines and cytokine networking in the pathogenesis in interstitial and fibrotic lung disorders.  Semir Respir Crit Care Med. 1994;  14 389-416
• 19 Boyle J E, Lindroos P M, Rice A B. et al . Prostaglandin-E2 counteracts interleukin-1beta-stimulated upregulation of platelet-derived growth factor alpha-receptor on rat pulmonary myofibroblasts.  Am J Respir Cell Mol Biol. 1999;  20 433-440
• 20 Phan S H, Kunkel S L. Lung cytokine production in bleomycin-induced pulmonary fibrosis.  Exp Lung Res. 1992;  18 29-43
• 21 Thrall R S, Scalise P J. Bleomycin. In: Phan SH (editor). Pulmonary Fibrosis. New York: Marcel Dekker 1995: 231-292
• 22 Pan L H, Ohtani H, Yamauchi K. et al . Co-expression of TNF alpha and IL-1 beta in human acute pulmonary fibrotic diseases: an immunohistochemical analysis.  Pathol Int. 1996;  46 91-99
• 23 Johnston C J, Piedboeuf B, Rubin P. et al . Early and persistent alterations in the expression of interleukin-1 alpha, interleukin-1 beta and tumor necrosis factor alpha mRNA levels in fibrosis-resistant and sensitive mice after thoracic irradiation.  Radiat Res. 1996;  145 762-767
• 24 Lee Y M, Hybertson B M, Cho H G. et al . Platelet-activating factor contributes to acute lung leak in rats given interleukin-1 intratracheally.  Am J Physiol Lung Cell Mol Physiol. 2000;  279 L75-L80
• 25 Hybertson B M, Lee Y M, Repine J E. Phagocytes and acute lung injury: dual roles for interleukin-1.  Ann NY Acad Sci. 1997;  832 266-273
• 26 Kolb M, Margetts P J, Anthony D C. et al . Transient expression of IL-1beta induces acute lung injury and chronic repair leading to pulmonary fibrosis.  J Clin Invest. 2001;  107 1529-1536
• 27 Kotecha S, Wilson L, Wangoo A. et al . Increase in interleukin (IL)-1 beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity.  Pediatr Res. 1996;  40 250-256
• 28 Sporn M B, Roberts A B. Peptide growth factors and their receptors. New York: Springer 1991
• 29 Tufvesson E, Westergren-Thorsson G. Alteration of proteoglycan synthesis in human lung fibroblasts induced by interleukin-1beta and tumor necrosis factor-alpha.  J Cell Biochem. 2000;  77 298-309
• 30 Ortiz L A, Lasky J, Hamilton Jr R F. et al . Expression of TNF and the necessity of TNF receptors in bleomycin-induced lung injury in mice.  Exp Lung Res. 1998;  24 721-743
• 31 Sime P J, Marr R A, Gauldie D. et al . Transfer of tumor necrosis factor-alpha to rat lung induces severe pulmonary inflammation and patchy interstitial fibrogenesis with induction of transforming growth factor-beta1 and myofibroblasts.  Am J Pathol. 1998;  153 825-832
• 32 Ziegenhagen M W, Schrum S, Zissel G. et al . Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis.  J Investig Med. 1998;  46 223-231
• 33 O'Kane S, Ferguson M W. Transforming growth factor beta s and wound healing.  Int J Biochem Cell Biol. 1997;  29 63-78
• 34 Letterio J J, Roberts A B. TGF-beta: a critical modulator of immune cell function.  Clin Immunol Immunopathol. 1997;  84 244-250
• 35 Munger J S, Huang X, Kawakatsu H. et al . The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis.  Cell. 1999;  96 319-328
• 36 Fish J E, Peters S P. Airway remodeling and persistent airway obstruction in asthma.  J Allergy Clin Immunol. 1999;  104 509-516
• 37 Mutsaers S E, Bishop J E, McGrouther G. et al . Mechanisms of tissue repair: from wound healing to fibrosis.  Int J Biochem Cell Biol. 1997;  29 5-17
• 38 Border W A, Noble N A. Transforming growth factor beta in tissue fibrosis.  N Engl J Med. 1994;  331 1286-1292
• 39 Rubin P, Johnston C J, Williams J P. et al . A perpetual cascade of cytokines postirradiation leads to pulmonary fibrosis [see comments].  Int J Radiat Oncol Biol Phys. 1995;  33 99-109
• 40 Sime P J, Xing Z, Graham F L. et al . Adenovector-mediated gene transfer of active transforming growth factor- beta1 induces prolonged severe fibrosis in rat lung.  J Clin Invest. 1997;  100 768-776
• 41 Anscher M S, Kong F M, Andrews K. et al . Plasma transforming growth factor beta1 as a predictor of radiation pneumonitis.  Int J Radiat Oncol Biol Phys. 1998;  41 1029-1035
• 42 Fabisiak J P, Kelley J. Platelet derived growth factor. In: Kelley J (editor). Cytokines of the lung. New York: Marcel Dekker 1993: 3-39
• 43 Rice A B, Moomaw C R, Morgan D L. et al . Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats.  Am J Pathol. 1999;  155 213-221
• 44 Lasky J A, Tonthat B, Liu J Y. et al . Upregulation of the PDGF-alpha receptor precedes asbestos-induced lung fibrosis in rats.  Am J Respir Crit Care Med. 1998;  157 1652-1657
• 45 Bostrom H, Willetts K, Pekny M. et al . PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis.  Cell. 1996;  85 863-873
• 46 Chung K F, Barnes P J. Cytokines in asthma.  Thorax. 1999;  54 825-857
• 47 Barrios R, Pardo A, Ramos C. et al . Upregulation of acidic fibroblast growth factor during development of experimental lung fibrosis.  Am J Physiol. 1997;  273 L451-L458
• 48 Liebler J M, Picou M A, Qu Z. et al . Altered immunohistochemical localization of basic fibroblast growth factor after bleomycin-induced lung injury.  Growth Factors. 1997;  14 25-38
• 49 Kadono T, Kikuchi K, Kubo M. et al . Serum concentrations of basic fibroblast growth factor in collagen diseases.  J Am Acad Dermatol. 1996;  35 392-397
• 50 Stern J B, Fierobe L, Paugam C. et al . Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients.  Crit Care Med. 2000;  28 2326-2333
• 51 Anscher M S, Peters W P, Reisenbichler H. et al . Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer.  N Engl J Med. 1993;  328 1592-1598
• 52 Vogel E, Kolb M, Mueller J. et al . BAL levels of the profibrotic cytokines TGFbeta and PDGF in patients with interstitial lung disease.  Eur Respir J. 2000;  14 369S
• 53 Piguet P F, Vesin C. Treatment by human recombinant soluble TNF receptor of pulmonary fibrosis induced by bleomycin or silica in mice.  Eur Respir J. 1994;  7 515-518
• 54 Piguet P F, Vesin C, Grau G E. et al . Interleukin 1 receptor antagonist (IL-1ra) prevents or cures pulmonary fibrosis elicited in mice by bleomycin or silica.  Cytokine. 1993;  5 57-61
• 55 Entzian P, Zahringer U, Schlaak M. et al . Comparative study on effects of pentoxifylline, prednisolone and colchicine in experimental alveolitis.  Int J Immunopharmacol. 1998;  20 723-735
• 56 Zabel P, Entzian P, Dalhoff K. et al . Pentoxifylline in treatment of sarcoidosis.  Am J Respir Crit Care Med. 1997;  155 1665-1669
• 57 Iyer S N, Gurujeyalakshmi G, Giri S N. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis.  J Pharmacol Exp Ther. 1999;  291 367-373
• 58 van den Berg W B. Anti-cytokine therapy in chronic destructive arthritis.  Arthritis Res. 2001;  3 18-26
• 59 Wang Q, Wang Y, Hyde D M. et al . Reduction of bleomycin induced lung fibrosis by transforming growth factor beta soluble receptor in hamsters.  Thorax. 1999;  54 805-812
• 60 Giri S N, Hyde D M, Braun R K. et al . Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis.  Biochem Pharmacol. 1997;  54 1205-1216
• 61 Giri S N, Hyde D M, Hollinger M A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice.  Thorax. 1993;  48 959-966
• 62 Kolb M, Margetts P J, Galt T. et al . Transient Transgene Expression of Decorin in the Lung Reduces the Fibrotic Response to Bleomycin.  Am J Respir Crit Care Med. 2001;  163 770-777
• 63 Molteni A, Moulder J E, Cohen E F. et al . Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker.  Int J Radiat Biol. 2000;  76 523-532
• 64 Gurujeyalakshmi G, Hollinger M A, Giri S N. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level.  Am J Physiol. 1999;  276 L311-L318
• 65 Gurujeyalakshmi G, Hollinger M A, Giri S N. Regulation of transforming growth factor-beta1 mRNA expression by taurine and niacin in the bleomycin hamster model of lung fibrosis.  Am J Respir Cell Mol Biol. 1998;  18 334-342
• 66 Ziesche R, Hofbauer E, Wittmann K. et al . A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis.  N Engl J Med. 1999;  341 1264-1269
• 67 Franklin T J. Therapeutic approaches to organ fibrosis.  Int J Biochem Cell Biol. 1997;  29 79-89
• 68 Marshall R P, McAnulty R J, Laurent G J. Angiotensin II is mitogenic for human lung fibroblasts via activation of the type 1 receptor.  Am J Respir Crit Care Med. 2000;  161 1999-2004
• 69 Yoshida M, Sakuma-Mochizuki J, Abe K. et al . In vivo gene transfer of an extracellular domain of platelet-derived growth factor beta receptor by the HVJ-liposome method ameliorates bleomycin-induced pulmonary fibrosis.  Biochem Biophys Res Commun. 1999;  265 503-508
• 70 Bienkowski R S, Gotkin M G. Control of collagen deposition in mammalian lung.  Proc Soc Exp Biol Med. 1995;  209 118-140
• 71 Gurujeyalakshmi G, Giri S N. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression.  Exp Lung Res. 1995;  21 791-808
• 72 Raghu G, Johnson W C, Lockhart D. et al . Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study.  Am J Respir Crit Care Med. 1999;  159 1061-1069
• 73 Unemori E N, Pickford L B, Salles A L. et al . Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo.  J Clin Invest. 1996;  98 2739-2745
• 74 Seibold J R, Korn J H, Simms R. et al . Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.  Ann Intern Med. 2000;  132 871-879